drugset / Trial / NCT00320489

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

NCT00320489

Phase 3 Completed 524 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.

Timeline

Start
2006-04
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 5 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Subject Olanzapine Small molecule 150 mg Intramuscular
Subject Olanzapine Small molecule 405 mg Intramuscular

Indications